Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Suwicha Limvorasak
Observed name:
S. Limvorasak
Institution:
Cedars-Sinai Medical Center
Observed institutions:
Cedars-Sinai Medical Center,
University of Michigan,
University of Chicago,
University of Chicago Medical Center,
University of Pittsburgh Medical Center
ORCID:
0000-0003-2360-5099
Observed ORCID:
0000-0003-2360-5099
OpenAlex ID:
A5078924974
Targeted therapies for renal cell carcinoma
2017
·
Edwin M. Posadas
, Suwicha Limvorasak
, et al.
·
Nature Reviews Nephrology
·
246
Targeting angiogenesis in renal cell carcinoma
2013
·
Edwin M Posadas
, Suwicha Limvorasak
, et al.
·
Expert Opinion on Pharmacotherapy
·
41
Pazopanib: therapeutic developments
2009
·
Suwicha Limvorasak
, Edwin M Posadas
·
Expert Opinion on Pharmacotherapy
·
30
Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group
2022
·
Heidi D Finnes
, Berrie Child
, et al.
·
American Journal of Health-System Pharmacy
·
24
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database
2011
·
Mosmi Surati
, Matthew Robinson
, et al.
·
Journal of Clinical Bioinformatics
·
13
PDF
Kinase Inhibitors in Prostate Cancer
2009
·
Suwicha Limvorasak
, Edwin M. Posadas
·
Anti-Cancer Agents in Medicinal Chemistry
·
5
Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report
2026
·
David W. Shia
, Suwicha Limvorasak
, et al.
·
JTO Clinical and Research Reports
·
1
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.
2023
·
Suwicha Limvorasak
, Kyung Kim
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Successful biosimilar adoption in oncology: strategic approach to system standardization.
2022
·
Suwicha Limvorasak
, Crystal Leung Dobbs
, et al.
·
Journal of Clinical Oncology
·
1
Third-Line Treatment Options for Kidney Cancer.
2016
·
Edwin M Posadas
, Suwicha Limvorasak
, et al.
·
PubMed
·
1
2433P Preliminary safety and clinical activity from a phase II study of apalutamide + carotuximab in advanced, castration-resistant prostate cancer
2025
·
E.M. Posadas
, U. Swami
, et al.
·
Annals of Oncology
QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC)
2022
·
Suwicha Limvorasak
, Hilary Teaford
, et al.
·
Journal of the National Comprehensive Cancer Network
Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.
2017
·
Edwin M. Posadas
, Jie-Fu Chen
, et al.
·
Journal of Clinical Oncology
A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study.
2011
·
J. E. Ward
, S. Limvorasak
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
15
Citation count:
363
H-index:
5
I10-index:
5
Year
Topic
Type
